Patients with inflammatory bowel disease (IBD) show high acceptance of adalimumab biosimilars, achieving positive outcomes and clinical remission after switching.

The biosimilar industry faces awareness challenges among health care professionals (HCPs), which must be addressed to ...

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory ...

Number 5: Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by strong denosumab biosimilars and expanding portfolios. Number 4: ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by ...

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to ...

Real-world study reveals comparable effectiveness of bevacizumab biosimilars and Avastin in metastatic colorectal cancer (CRC ...

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and ...

New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for ...